These findings position the STEAP4+ myoCAF‐TFE3/tumor‐HIF1A axis as a master regulator of anti‐androgen resistance, offering clinically actionable targets to extend treatment efficacy in advanced prostate cancer. The gene discussed is HIF1A; the disease is Familial prostate cancer.